Navigation Links
Rib-X Pharmaceuticals to Present at the 49th ICAAC
Date:9/10/2009

NEW HAVEN, Conn., Sept. 10 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of acute care antibiotic-resistant infections, today announced that seven posters have been accepted for presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in San Francisco, CA on September 12-15, 2009. Details on these presentations are as follows:


                                                                 Location/
                                                                 Poster/
    Date      Time      Session         Title                    Presentation

    Sept. 13  11:15am-  Oxazolidinones  In Vitro Activity of     Hall B
              1:15pm                    Radezolid against MRSA   Poster #277
                                        Causing Skin and Wound   Present-
                                        Infections from the      ation
                                        United States, Europe,   #E-810
                                        and Asia

    Sept. 13  11:15am-  New Research    Novel Antibiotic Classes Hall B
              1:15pm    Technologies    to Treat Gram-Negative   Poster #332
                        and             Infections               Present-
                        Methodologies                            ation
                                                                 #F2-861

    Sept. 14  11:15am-  Antibiotic      Anti-MRSA Properties of  Hall B
              1:15pm    Resistance in   Delafloxacin: Mutant     Poster #101
                        Staphylococcus  Analysis and             Present-
                        aureus          Characterization         ation
                                                                 #C1-1363

    Sept. 15  9:00am-   PK/PD           Clinical Trial Dose      Hall D
              11:00am   Investigational Selection for            Poster #15
                        Antibacterials  Delafloxacin (DFX) for   Present-
                                        Complicated Skin and     ation
                                        Skin-Structure           #A1-1942
                                        Infections (cSSSI)

    Sept. 15  9:00am-   New Macrolides  Enhanced Macrolides:     Hall D
              11:00am   and Ketolides   Optimized Molecular      Poster #125
                                        Properties for Oral      Present-
                                        Exposure                 ation
                                                                 #F1-2049

    Sept. 15  9:00am-   New Macrolides  Enhanced Macrolides:     Hall D
              10:00am   and Ketolides   Overcoming Resistance    Poster #126
                                        by Improving Target      Present-
                                        Affinity                 ation
                                                                 #F1-2050

    Sept. 15  9:00am-   PK/PD           Pharmacokinetics and     Hall D
              11:00am   Investigational Pharmacodynamics of      Poster #14
                        Antibacterials  Delafloxacin in S.       Present-
                                        aureus Murine Thigh      ation
                                        Infection Models         #A1-1941


"It is very satisfying to present for critical review the scientific developments Rib-X has fostered during the past year and in four distinctive antibiotic programs. It is especially rewarding to receive input from our peers at the premier anti-infective conference," said Susan Froshauer, PhD, President and Chief Executive Officer, Rib-X Pharmaceuticals. "We are particularly pleased to present proof-of-concept data on our novel chemical class Gram-negative program."

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. In addition to Rx-04, Rib-X has successfully completed Phase 2 trials with delafloxacin (RX-3341), a broad spectrum fluoroquinolone with potent activity against quinolone resistant Gram-positive bacteria including MRSA. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections has completed two Phase 2 trials and the Rx-02 discovery program which is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes. Both delafloxacin and radezolid are currently in late stage clinical trials.

For more information on the Rib-X mission and the pipeline, please visit the Company website at www.rib-x.com.

For further information please contact:

    Media:
    Irma Gomez-Dib
    FD Life Sciences
    Tel: 212-850-5761
    irma.gomez-dib@fd.com

    Investors:
    John Capodanno
    FD Life Sciences
    Tel: 212-850-5705
    John.capodanno@fd.com


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
2. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
3. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
4. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
5. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
6. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
7. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
8. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
9. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
10. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
11. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Florida , February 11, 2016 ... and Promote Genetic Understanding to Support Research and Discovery ... GenomeAsia 100K, today announced an ambitious plan to sequence 100,000 ... South Asian countries and at least 7 of North and ... In the first phase, the project will focus on ...
(Date:2/11/2016)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytical solutions ... of the Steering Committee for its Pelvic Mass Registry. ... Pelvic masses can present physicians and healthcare professionals with ... ruled out, pelvic masses may include cancers of the ... tumors and gastrointestinal and urinary tract masses. ...
(Date:2/11/2016)... , Feb. 11, 2016  Bioethics International, a not-for-profit organization ... researched, developed, marketed and made accessible to patients around the ... had named the publication of the Good Pharma ... publication is also featured as one of BMJ Open ... last year that are most frequently read. Ed ...
(Date:2/11/2016)...  Wellcentive today announced it has been selected ... -based community care organization (CCO) with more than ... reporting and care management solutions and services. Wellcentive,s ... quality managers, analysts and care managers while providing ... FamilyCare members. Oregon ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):